Prognostication of Uveal Melanoma by Fine Needle Aspiration (FNA) and Fluorescence in Situ Hybridization (FlSH)
- To establish the feasibility of using fine needle aspiration (FNA) and FISH to
determine tumor genotype in patients with primary uveal melanoma.
- To characterize ophthalmic complication rate of FNA for FISH analysis in patients
undergoing plaque radiotherapy.
- To estimate disease-free survival in patients with and without tumor monosomy 3 and/or
- To explore the relationship between tumor monosomy 3 and 8q amplification and plasma
levels of tumor immune escape and invasion biomarkers (e.g., circulating granulysin,
beta2-microglobulin, autotoxin, lysophosphatidic acid, matrix metalloproteinase-7,
tissue inhibitor of matrix metalloproteinase, and soluble E- cadherin).
- To explore the psychological impact of prognostication in uveal melanoma.
OUTLINE: Patients undergo plaque radiotherapy, enucleation, or tumor resection based upon
standard of care guidelines.
Trans-scleral fine needle aspiration (FNA) is performed at the time of plaque radiotherapy
and ex vivo FNA is performed on enucleation and tumor resection specimens. Tissue samples
are analyzed by fluorescence in situ hybridization (FISH). Blood samples are also collected
for further analysis.
After completion of study therapy, patients are followed up periodically.
Observational Model: Case-Only, Time Perspective: Prospective
Number of patients that have Disease Free Survival (DFS) with primary uveal melanoma with and without high-risk genotypes
DFS will be measured from the date of initial treatment to the date of documented recurrence or death. It will be summarized using the method of Kaplan and Meier.
Arun D. Singh, MD
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
United States: Institutional Review Board
|Cleveland Clinic Cole Eye Institute||Cleveland, Ohio 44195|